Segments (Tables)

6 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

Information by Reportable Segment

Segment Adjusted EBITDA by reportable segment was as follows:

	Three Months Ended   June 30,				Six Months Ended   June 30,
	2024		2023		2024		2023
Biopharmaceuticals	$	(27,574)	$	(17,254)	$	(51,394)	$	(38,597)
Exemplar	(483)		(83)		(683)		38
Segment Adjusted EBITDA for reportable segments	$	(28,057)	$	(17,337)	$	(52,077)	$	(38,559)

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss before income taxes:

	Three Months Ended   June 30,				Six Months Ended   June 30,
	2024		2023		2024		2023
Segment Adjusted EBITDA for reportable segments	$	(28,057)	$	(17,337)	$	(52,077)	$	(38,559)
Remove cash paid for capital expenditures, net of proceeds from sale of assets	2,326		101		6,674		255
Interest Income	319		828		927		1,461
Other expenses:
Interest expense	(2)		(136)		(4)		(460)
Depreciation and amortization	(1,596)		(1,693)		(3,191)		(3,404)
Gain on disposals of assets	—		40		3		40
Impairment losses	(34,545)		—		(34,545)		—
Stock-based compensation expense	(1,964)		(2,188)		(4,545)		(5,320)
Adjustment related to accrued bonuses paid in equity awards	3,039		—		3,039		3,360
Shares issue for payment of services	—		—		(528)		(545)
Other	(1)		1		(1)		(1)
Consolidated loss before income taxes	$	(60,481)	$	(20,384)	$	(84,248)	$	(43,173)